Lifting the innate immune barriers to antitumor immunity

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

(2019) Alessio Cortellini et al.   Journal for ImmunoTherapy of Cancer

LC3-associated phagocytosis at a glance

(2019) Bradlee L. Heckmann et al.   JOURNAL OF CELL SCIENCE

MERTK tyrosine kinase receptor together with TIM4 phosphatidylserine receptor mediates distinct signal transduction pathways for efferocytosis and cell proliferation

(2019) Chihiro Nishi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Enhancing tumor T cell infiltration to enable cancer immunotherapy

(2019) Jin Zhang et al.   Immunotherapy

Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.

(2019) Funda Meric-Bernstam et al.   JOURNAL OF CLINICAL ONCOLOGY

CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy

(2019) Weimin Wang et al.   NATURE

The metalloprotease ADAM17 in inflammation and cancer

(2019) Stefan Düsterhöft et al.   PATHOLOGY RESEARCH AND PRACTICE

Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies

(2019) Ivan Perrot et al.   Cell Reports

Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study

(2019) Natasha B Leighl et al.   Lancet Respiratory Medicine

Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity

(2019) Laurent Gauthier et al.   CELL

CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy

(2019) Amira A. Barkal et al.   NATURE

Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity

(2019) Annelise G. Snyder et al.   Science Immunology

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

(2019) Georgina V Long et al.   LANCET ONCOLOGY

TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti–PD-1 Therapy in Melanoma

(2019) Alisha Holtzhausen et al.   Cancer Immunology Research

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

(2018) Rizwan Romee et al.   BLOOD

NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control

(2018) Jan P. Böttcher et al.   CELL

Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response

(2018) Eric Ubil et al.   JOURNAL OF CLINICAL INVESTIGATION

A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments

(2018) Kevin C. Barry et al.   NATURE MEDICINE

The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients

(2018) Vyara Matson et al.   SCIENCE

Coming of Age: CD96 Emerges as Modulator of Immune Responses

(2018) Hristo Georgiev et al.   Frontiers in Immunology

The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy

(2018) Lilla Hornyák et al.   Frontiers in Immunology

Mutation load estimation model as a predictor of the response to cancer immunotherapy

(2018) Guan-Yi Lyu et al.   npj Genomic Medicine

Tim-4 promotes the growth of colorectal cancer by activating angiogenesis and recruiting tumor-associated macrophages via the PI3K/AKT/mTOR signaling pathway

(2018) Xiao Tan et al.   CANCER LETTERS

LC3-Associated Phagocytosis in Myeloid Cells Promotes Tumor Immune Tolerance

(2018) Larissa D. Cunha et al.   CELL

Innate Lymphoid Cells: 10 Years On

(2018) Eric Vivier et al.   CELL

Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade

(2018) Joy Hsu et al.   JOURNAL OF CLINICAL INVESTIGATION

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

LBA15Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas

(2018) K J Harrington et al.   ANNALS OF ONCOLOGY

NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines

(2018) Nadine van Montfoort et al.   CELL

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells

(2018) Pascale André et al.   CELL

Putting the Immunologic Brakes on Cancer

(2018) Jedd Wolchok   CELL

Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis

(2018) Brian W. Labadie et al.   CLINICAL CANCER RESEARCH

Immune Checkpoint Inhibitor Toxicity in 2018

(2018) Douglas B. Johnson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade

(2018) Ziming Wang et al.   NATURE MEDICINE

The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets

(2017) Bertrand Allard et al.   IMMUNOLOGICAL REVIEWS

LAG3 (CD223) as a cancer immunotherapy target

(2017) Lawrence P. Andrews et al.   IMMUNOLOGICAL REVIEWS

TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy

(2017) William C. Dougall et al.   IMMUNOLOGICAL REVIEWS

Current prospects of type II interferon γ signaling and autoimmunity

(2017) Daniel S. Green et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

LC3-Associated Phagocytosis and Inflammation

(2017) Bradlee L. Heckmann et al.   JOURNAL OF MOLECULAR BIOLOGY

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

(2017) Aaron M. Goodman et al.   MOLECULAR CANCER THERAPEUTICS

IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity

(2017) Martina Molgora et al.   NATURE

Macrophage function in tissue repair and remodeling requires IL-4 or IL-13 with apoptotic cells

(2017) Lidia Bosurgi et al.   SCIENCE

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

(2017) V. Gopalakrishnan et al.   SCIENCE

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

(2017) Bertrand Routy et al.   SCIENCE

Negative Regulation of Cytokine Signaling in Immunity

(2017) Akihiko Yoshimura et al.   Cold Spring Harbor Perspectives in Biology

High IL-1R8 expression in breast tumors promotes tumor growth and contributes to impaired antitumor immunity

(2017) Luis Felipe Campesato et al.   Oncotarget

Myeloid-Derived Suppressor Cells

(2017) Dmitry I. Gabrilovich   Cancer Immunology Research

Chronicles of Cell Death Foretold: Specificities in the Mechanism of Disposal

(2017) Lindsey D. Hughes et al.   Frontiers in Immunology

Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications

(2017) Mariona Cabo et al.   OncoImmunology

Critical Role for CD103 + /CD141 + Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma

(2016) Edward W. Roberts et al.   CANCER CELL

BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection—Implications for Oncolytic Viral Therapy

(2016) Chelsea Bolyard et al.   CLINICAL CANCER RESEARCH

Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy

(2016) S. J. Blake et al.   CLINICAL CANCER RESEARCH

Expansion and Activation of CD103 + Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition

(2016) Hélène Salmon et al.   IMMUNITY

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

(2016) Ana C. Anderson et al.   IMMUNITY

PI3Kγ is a molecular switch that controls immune suppression

(2016) Megan M. Kaneda et al.   NATURE

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

PGE2 induced in and released by dying cells functions as an inhibitory DAMP

(2016) Sho Hangai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The TAM family receptor tyrosine kinase TYRO3 is a negative regulator of type 2 immunity

(2016) P. Y. Chan et al.   SCIENCE

Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy

(2016) S. J. Blake et al.   Cancer Discovery

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer

(2016) Valsamo Anagnostou et al.   Cancer Discovery

Antibody-Mediated Phosphatidylserine Blockade Enhances the Antitumor Responses to CTLA-4 and PD-1 Antibodies in Melanoma

(2016) B. D. Freimark et al.   Cancer Immunology Research

Inhibition of Soluble Tumor Necrosis Factor Prevents Chemically Induced Carcinogenesis in Mice

(2016) A. Sobo-Vujanovic et al.   Cancer Immunology Research

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

(2016) J. Weber et al.   Cancer Immunology Research

Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors

(2016) Rikke B. Holmgaard et al.   EBioMedicine

TAM Receptor Signaling in Immune Homeostasis

(2015) Carla V. Rothlin et al.   Annual Review of Immunology

TIM-4 promotes the growth of non-small-cell lung cancer in a RGD motif-dependent manner

(2015) Qianqian Zhang et al.   BRITISH JOURNAL OF CANCER

Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo

(2015) Ali Roghanian et al.   CANCER CELL

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma

(2015) J. A. Califano et al.   CLINICAL CANCER RESEARCH

Targeting the tumor vasculature to enhance T cell activity

(2015) Evripidis Lanitis et al.   CURRENT OPINION IN IMMUNOLOGY

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

(2015) Stefani Spranger et al.   NATURE

IL-37 requires the receptors IL-18Rα and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction

(2015) Claudia A Nold-Petry et al.   NATURE IMMUNOLOGY

Control of adaptive immunity by the innate immune system

(2015) Akiko Iwasaki et al.   NATURE IMMUNOLOGY

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity

(2014) Miranda L. Broz et al.   CANCER CELL

Tadalafil Reduces Myeloid-Derived Suppressor Cells and Regulatory T Cells and Promotes Tumor Immunity in Patients with Head and Neck Squamous Cell Carcinoma

(2014) D. T. Weed et al.   CLINICAL CANCER RESEARCH

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

(2014) Seng-Ryong Woo et al.   IMMUNITY

Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution

(2014) Jamie C. Stanford et al.   JOURNAL OF CLINICAL INVESTIGATION

ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R–mediated apoptosis

(2014) Thomas Condamine et al.   JOURNAL OF CLINICAL INVESTIGATION

P2X7 Receptor Differentially Couples to Distinct Release Pathways for IL-1  in Mouse Macrophage

(2014) P. Pelegrin et al.   JOURNAL OF IMMUNOLOGY

The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions

(2014) Christopher J Chan et al.   NATURE IMMUNOLOGY

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab

(2014) Ahmad A. Tarhini et al.   PLoS One

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

(2014) K. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy

(2014) S. L. Highfill et al.   Science Translational Medicine

Targeting Immune Suppression with PDE5 Inhibition in End-Stage Multiple Myeloma

(2014) K. A. Noonan et al.   Cancer Immunology Research

Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade

(2014) I. P. da Silva et al.   Cancer Immunology Research

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab

(2013) Christiane Meyer et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A Chimeric Receptor with NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor Cells

(2013) Y.-H. Chang et al.   CANCER RESEARCH

T Cell-Derived Protein S Engages TAM Receptor Signaling in Dendritic Cells to Control the Magnitude of the Immune Response

(2013) Eugenio A. Carrera Silva et al.   IMMUNITY

TIM-4 Glycoprotein-Mediated Degradation of Dying Tumor Cells by Autophagy Leads to Reduced Antigen Presentation and Increased Immune Tolerance

(2013) Muhammad Baghdadi et al.   IMMUNITY

MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis

(2013) Rebecca S. Cook et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

(2013) C. Feig et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity

(2012) L. C. Ndhlovu et al.   BLOOD

Elevated Epidermal Thymic Stromal Lymphopoietin Levels Establish an Antitumor Environment in the Skin

(2012) Shadmehr Demehri et al.   CANCER CELL

Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas

(2012) Muhammad Baghdadi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Targeting the Interleukin-6/Jak/Stat Pathway in Human Malignancies

(2012) Pasquale Sansone et al.   JOURNAL OF CLINICAL ONCOLOGY

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

(2012) S. B. Willingham et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Indoleamine 2,3 dioxygenase and metabolic control of immune responses

(2012) David H. Munn et al.   TRENDS IN IMMUNOLOGY

Type I interferon response and innate immune sensing of cancer

(2012) Mercedes B. Fuertes et al.   TRENDS IN IMMUNOLOGY

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy

(2011) S. H. Lim et al.   BLOOD

An immune-active tumor microenvironment favors clinical response to ipilimumab

(2011) Rui-Ru Ji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis

(2011) J. Stagg et al.   CANCER RESEARCH

Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells

(2011) Mercedes B. Fuertes et al.   JOURNAL OF EXPERIMENTAL MEDICINE

VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses

(2011) Li Wang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Brain angiogenesis inhibitor 1 (BAI1) is a pattern recognition receptor that mediates macrophage binding and engulfment of Gram-negative bacteria

(2011) Soumita Das et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

ADAM17: a molecular switch to control inflammation and tissue regeneration

(2011) Jürgen Scheller et al.   TRENDS IN IMMUNOLOGY

5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity

(2010) J. Vincent et al.   CANCER RESEARCH

CD39/ENTPD1 Expression by CD4+Foxp3+ Regulatory T Cells Promotes Hepatic Metastatic Tumor Growth in Mice

(2010) Xiaofeng Sun et al.   GASTROENTEROLOGY

Tumor-Induced Tolerance and Immune Suppression Depend on the C/EBPβ Transcription Factor

(2010) Ilaria Marigo et al.   IMMUNITY

Modulation of Paired Immunoglobulin-Like Type 2 Receptor Signaling Alters the Host Response to Staphylococcus aureus-Induced Pneumonia

(2010) A. Banerjee et al.   INFECTION AND IMMUNITY

Identification of Endothelial Cell Junctional Proteins and Lymphocyte Receptors Involved in Transendothelial Migration of Human Effector Memory CD4+ T Cells

(2010) T. D. Manes et al.   JOURNAL OF IMMUNOLOGY

Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis

(2010) J. Stagg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein- 

(2010) M. Kraman et al.   SCIENCE

Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47

(2010) M. P. Chao et al.   Science Translational Medicine

Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6

(2009) S. Loges et al.   BLOOD

NK cell-mediated killing of target cells triggers robust antigen-specific T cell-mediated and humoral responses

(2009) P. Krebs et al.   BLOOD

CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis

(2009) Siddhartha Jaiswal et al.   CELL

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

(2009) Ravindra Majeti et al.   CELL

Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice

(2009) Hanh K. Le et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Lack of Protein S in mice causes embryonic lethal coagulopathy and vascular dysgenesis

(2009) Tal Burstyn-Cohen et al.   JOURNAL OF CLINICAL INVESTIGATION

Adaptive immune features of natural killer cells

(2009) Joseph C. Sun et al.   NATURE

TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization

(2009) Cecilia Garlanda et al.   TRENDS IN IMMUNOLOGY

Adenosine receptors in regulation of dendritic cell differentiation and function

(2008) S. V. Novitskiy et al.   BLOOD

Type I interferon as a stimulus for cross-priming

(2008) A LEBON et al.   CYTOKINE & GROWTH FACTOR REVIEWS

When Signaling Pathways Collide: Positive and Negative Regulation of Toll-like Receptor Signal Transduction

(2008) Luke A.J. O'Neill   IMMUNITY

Vascular normalization in Rgs5-deficient tumours promotes immune destruction

(2008) Juliana Hamzah et al.   NATURE

Batf3 Deficiency Reveals a Critical Role for CD8 + Dendritic Cells in Cytotoxic T Cell Immunity

(2008) K. Hildner et al.   SCIENCE